Presence of Promising Pipeline to Ensure Healthy Growth of Pulmonary Arterial Hypertension (PAH) Market in Developed Regions

There has been an increased prevalence of pulmonary arterial hypertension (PAH) in the past few years. The growing number of cases of PAH can be attributed to sedentary lifestyle, increased number of people who smoke, and rising alcohol and tobacco consumption. The rising incidences of HIV and idiopathic conditions among people are also contributing to the growing prevalence of pulmonary arterial hypertension among people across the globe. As per Transparency Market Research (TMR), a market intelligence and research firm, the global pulmonary arterial hypertension market is estimated to be worth US$5.19 bn by 2020.

Given below are some of the questions answered by TMR analysts on the global PAH market:

Q. What are the key factors aiding the growth of this market?

PAH is a disorder, which may occur in association with other diseases of the lungs and heart. As the number of people suffering from cardiac and lung diseases is increasing, it is benefitting the global PAH market. Tissue disorders, blood clots, high blood pressure, connective tissue disorders, coronary artery disorders, and congenital heart disorders, are some of the causes of PAH and with the growing incidences of these conditions among people, the risk of PAH is increasing, fueling the demand for PAH treatment options. 

The presence of a large population who are aged is also aiding the growth of the market as this population base show a higher tendency to acquire this disorder owing to their low immunity levels. Another factor supporting the growth of the pulmonary arterial hypertension market is the supportive legislations in countries such as the U.S., wherein the Rare Disease Act and Orphan Drug Act (ODA) facilitate the distribution and ethical use of orphan drugs.  The tax benefits offered by these legislations and the funding for clinical research on rare diseases are also helping the market to grow. 

Q. What are the factors restricting the PAH market’s growth?

The loss of exclusiveness of key drugs of this domain has had a considerable impact on the pulmonary arterial hypertension market. This in turn is dissuading and discouraging companies in the pharmaceutical sector to invest much in the research and development for developing new drugs. As PAH is still considered as a rare disease, the market size is relatively small as is the target population. Thus, many drug developers are hesitant to invest their money and time in the development or research of the treatment drugs for PAH.

Q. Which region is most likely to emerge promising in the PAH market in the years to come?

North America not only is leading at present in the market but shall continue to do so through 2020, followed by Europe. The accessibility to newly-approved pulmonary arterial hypertension drugs will be driving factor for both these regions. In addition to this, there lies a promising pipeline for PAH drugs and this will also ensure that these regions will show promising growth opportunities in the future. The growing awareness among the people in the developed nations about the availability of treatment options for PAH will also help the market to grow within Europe and North America. It is estimated that Asia Pacific will also show a remarkable growth in the near future with India, Japan, New Zealand, and China being the key nations which will see emergence of global players. The Rest of the World on the other hand is expected to face sluggish growth on account of lack of awareness about the availability of treatment as well as failure to detect PAH. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports